Patents by Inventor James D. McIninch

James D. McIninch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240124882
    Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a prion protein (PRNP) gene, as well as methods of inhibiting expression of a PRNP gene and methods of treating subjects having a PRNP-associated disease or disorder, e.g., Prion diseases, using such dsRNAi agents and compositions.
    Type: Application
    Filed: August 22, 2023
    Publication date: April 18, 2024
    Inventors: Haiyan Peng, Bret Lee Bostwick, James D. McIninch, Mark K. Schlegel, Adam Castoreno, Tuyen M. Nguyen
  • Patent number: 11959081
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the transthyretin (TTR) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an TTR gene and to methods of preventing and treating an TTR-associated disorder, e.g., senile systemic amyloidosis (SSA), systemic familial amyloidosis, familial amyloidotic polyneuropathy (FAP), familial amyloidotic cardiomyopathy (FAC), leptomeningeal/Central Nervous System (CNS) amyloidosis, and hyperthyroxinemia.
    Type: Grant
    Filed: September 28, 2022
    Date of Patent: April 16, 2024
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Mark K. Schlegel, Adam Castoreno, James D. McIninch
  • Patent number: 11926832
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the ketohexokinase (KHK) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KHK gene and to methods of treating or preventing a KHK-associated disorder in a subject.
    Type: Grant
    Filed: December 2, 2022
    Date of Patent: March 12, 2024
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Leila Noetzli, James D. McIninch, Frederic Tremblay, Mark K. Schlegel, Adam Castoreno
  • Publication number: 20240067972
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the dipeptidyl peptidase 4 (DPP4) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a DPP4 gene and to methods of treating or preventing a DPP4-associated disease, such as metabolic diseases, e.g., diabetes or lipid metabolism diseases, in a subject.
    Type: Application
    Filed: March 23, 2023
    Publication date: February 29, 2024
    Inventors: James D. McIninch, Lucas D. BonDurant
  • Publication number: 20240018515
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the complement factor B (CFB) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a CFB gene and to methods of treating or preventing a CFB-associated disease in a subject.
    Type: Application
    Filed: October 27, 2022
    Publication date: January 18, 2024
    Inventors: James D. McIninch, Adam Castoreno, Mark K. Schlegel, Elane Fishilevich, Kristina Yucius, Charalambos Kaittanis
  • Patent number: 11866710
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Transmembrane protease, serine 6 (TMPRSS6) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a TMPRSS6 gene and to methods of preventing and treating a TMPRSS6-associated disorder, e.g., a disorder associated with iron overload and/or a disorder of ineffective erythropoiesis, e.g., hereditary hemochromatosis, ?-thalassemia (e.g., ?-thalassemia major and ?-thalassemia intermedia), polycythemia vera, myelodysplastic syndrome, congenital dyserythropoietic anemias, pyruvate kinase deficiency, erythropoietic porphyria, Parkinson's Disease, Alzheimer's Disease or Friedreich's Ataxia.
    Type: Grant
    Filed: January 6, 2023
    Date of Patent: January 9, 2024
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Aimee M. Deaton, John Michael Gansner, James D. McIninch, Mark K. Schlegel, Benjamin P. Garfinkel
  • Publication number: 20230416736
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the mucin 5B (MUC5B) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a MUC5B gene and to methods of treating or preventing a MUC5B-associated disease, such as a lung disease, e.g., cystic fibrosis, chronic obstructive pulmonary disease (COPD), and/or pulmonary fibrosis, e.g., idiopathic pulmonary fibrosis (IPF), in a subject.
    Type: Application
    Filed: April 19, 2023
    Publication date: December 28, 2023
    Inventors: Leila Noetzli, Margaret Parker, James D. McIninch, Mark K. Schlegel, Adam Castoreno, Jeffrey Zuber
  • Publication number: 20230416748
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the ketohexokinase (KHK) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KHK gene and to methods of treating or preventing a KHK-associated disease in a subject.
    Type: Application
    Filed: September 1, 2022
    Publication date: December 28, 2023
    Inventors: Frederic Tremblay, James D. McIninch
  • Publication number: 20230392156
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the G-protein coupled receptor 75 (GPR75) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a GPR75 gene and to methods of treating or preventing a GPR75-associated disease, such as a body weight disorder, e.g., obesity, in a subject.
    Type: Application
    Filed: April 3, 2023
    Publication date: December 7, 2023
    Applicants: Alnylam Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc.
    Inventors: James D. McIninch, Bret Lee Bostwick, Adam Castoreno
  • Publication number: 20230392152
    Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a Huntingtin (HTT) gene, as well as methods of inhibiting expression of an HTT gene and methods of treating subjects having an HTT-associated disease or disorder, e.g., Huntington's disease, using such dsRNAi agents and compositions.
    Type: Application
    Filed: June 1, 2023
    Publication date: December 7, 2023
    Inventors: Mangala Meenakshi Soundarapandian, James D. McIninch, Mark K. Schlegel, Adam Castoreno
  • Publication number: 20230340485
    Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting an anaplastic lymphoma kinase (ALK) gene, as well as methods of inhibiting expression of an ALK gene and methods of treating subjects having an ALK-associated disease or disorder, e.g., type 2 diabetes, obesity, or an obesity-associated disorder, using such dsRNAi agents and compositions.
    Type: Application
    Filed: June 15, 2021
    Publication date: October 26, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: BRET L. BOSTWICK, JAMES D. MCININCH
  • Publication number: 20230332147
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the GRB 10 or GRB 14 gene, as well as methods of inhibiting expression of GRB 10 or GRB 14, and methods of treating subjects that would benefit from reduction in expression of GRB 10 or GRB 14, such as subjects having a GRB 10- or GRB 14-associated disease, disorder, or condition, such as diabetes, using such dsRNA compositions.
    Type: Application
    Filed: September 9, 2021
    Publication date: October 19, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: JAMES D. MCININCH, AIMEE DEATON, LUCAS BONDURANT, MARK K. SCHLEGEL, ADAM CASTORENO
  • Publication number: 20230323357
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TRAF6 gene, as well as methods of inhibiting expression of TRAF6, and methods of treating subjects that would benefit from reduction in expression of TRAF6, such as subjects having a TRAF6-associated disease, disorder, or condition, using such dsRNA compositions.
    Type: Application
    Filed: June 8, 2021
    Publication date: October 12, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: ARLIN ROGERS, MELISSA MOBLEY, JAMES D. MCININCH
  • Publication number: 20230323363
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the ketohexokinase (KHK) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KHK gene and to methods of treating or preventing a KHK-associated disorder in a subject.
    Type: Application
    Filed: December 2, 2022
    Publication date: October 12, 2023
    Inventors: Leila Noetzli, James D. McIninch, Frederic Tremblay, Mark K. Schlegel, Adam Castoreno
  • Publication number: 20230295622
    Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting MYOC, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of MYOC.
    Type: Application
    Filed: April 6, 2021
    Publication date: September 21, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: MARK KEATING, JAMES D. MCININCH
  • Publication number: 20230287432
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the G protein-coupled receptor 146 (GPR146). The invention also relates to methods of using such RNAi agents to inhibit expression of a GPR146 gene and to methods of preventing and treating a GPR146-associated disorders, e.g., hypercholesterolemia and atherosclerosis.
    Type: Application
    Filed: February 26, 2021
    Publication date: September 14, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: KEVIN FITZGERALD, FREDERIC TREMBLAY, JAMES D. MCININCH
  • Publication number: 20230272382
    Abstract: The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the complement component C3 gene and methods of using such iRNA agents for treating or preventing C3-associated ocular diseases or C3-associated neurodegenerative diseases.
    Type: Application
    Filed: September 1, 2022
    Publication date: August 31, 2023
    Inventors: Mark Keating, James D. McIninch
  • Publication number: 20230257749
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the complement factor B (CFB) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a CFB gene and to methods of treating or preventing a CFB-associated disease in a subject.
    Type: Application
    Filed: March 22, 2023
    Publication date: August 17, 2023
    Inventors: James D. McIninch, Mark K. Schlegel, Adam Castoreno, Elane Fishilevich, Kristina Yucius
  • Publication number: 20230220396
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Transmembrane protease, serine 6 (TMPRSS6) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a TMPRSS6 gene and to methods of preventing and treating a TMPRSS6-associated disorder, e.g., a disorder associated with iron overload and/or a disorder of ineffective erythropoiesis, e.g., hereditary hemochromatosis, ?-thalassemia (e.g., ?-thalassemia major and ?-thalassemia intermiedia), polycythemia vera, myelodysplastic syndrome, congenital dyserythropoietic anemias, pyruvate kinase deficiency, erythropoietic porphyria, Parkinson's Disease, Alzheimer's Disease or Friedreich's Ataxia.
    Type: Application
    Filed: January 6, 2023
    Publication date: July 13, 2023
    Inventors: Aimee M. Deaton, John Michael Gansner, James D. McIninch, Mark K. Schlegel, Benjamin P. Garfinkel
  • Publication number: 20230203486
    Abstract: The disclosure relates to double stranded ribonucleic acid interference (dsRNAi) agents and compositions targeting a microtubule-associated protein tau (MAPT) gene, as well as methods of inhibiting expression of a MAPT gene and methods of treating subjects having a MAPT-associated disease or disorder, e.g., Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, or other tauopathies, using such dsRNAi agents and compositions.
    Type: Application
    Filed: March 30, 2021
    Publication date: June 29, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: MANGALA MEENAKSHI SOUNDARAPANDIAN, JAMES D. MCININCH, ELANE FISHILEVICH, ADAM CASTORENO, CHARALAMBOS KAITTANIS, MARK K. SCHLEGEL, JONATHAN EDWARD FARLEY, JEFFREY ZUBER